Document:

Exhibit 10.38

 

 

 

CIT Group Inc. 

 Omnibus Incentive Plan

Restricted Stock Unit Director Award Agreement

 

“Date of Award”:

 

“Participant”:

“RSUs
Granted:

 

This Director Award Agreement, effective
as of the Date of Award set forth above, sets forth the grant of Restricted Stock Units (“RSUs”) by CIT Group
Inc., a Delaware corporation (the “Company”), to the Participant named above, pursuant to the provisions of
the CIT Group Inc. 2016 Omnibus Incentive Plan (the “Plan”). All capitalized terms shall have the meanings ascribed
to them in the Plan, unless specifically set forth otherwise herein.

 

The parties hereto agree as follows:

		(A)	Grant of RSUs.  The Company hereby grants to the Participant the number of
RSUs set forth above, subject to the terms and conditions of the Plan and this Director Award Agreement. Each RSU represents the
unsecured right to receive in the future one Share or a cash payment equal to the Fair Market Value of one Share. The Participant
shall not be required to pay any additional consideration for the issuance of the Shares or cash payment equal to the value of
the Shares upon settlement of the RSUs.

		(B)	Vesting and Settlement of RSUs. Subject to Sections (C) and (D) all RSUs shall vest
and settle in accordance with the provisions of this Section (B).

		(1)	One-third of the RSUs granted shall vest,
on a cumulative basis, on [l];
provided, however, the RSUs shall be subject to earlier vesting in accordance with Sections (C)(1) and (D) hereof. The date on
which each RSU vests is referred to as the “Vesting Date”.

		(2)	Each vested RSU shall be settled within forty-five
(45) days following the applicable Vesting Date (each a “Settlement Date”). On each applicable Settlement Date,
fifty percent (50%) of the then vested RSUs shall be settled through the delivery of Shares and the remaining fifty percent (50%)
shall be settled through a payment in cash equal to the Fair Market Value of the applicable number of Shares in respect of such
RSUs on the applicable Vesting Date or, in the case of settlement in accordance with Sections (C)(1) or (D), as applicable, the
date of the Participant’s death, Disability, Approved Departure or the effective date of the Change of Control.

		(3)	Any Shares delivered to the Participant on
the applicable Settlement Date (or such earlier date determined in accordance with Sections (C)(1) or (D)) shall not be subject
to transfer restrictions and shall be fully paid, non-assessable and registered in the Participant’s name.

		(4)	If, after the Date of Award and prior to the
applicable Vesting Date, dividends with respect to Shares are declared or paid by the Company, the Participant shall be entitled
to receive dividend equivalents in an amount, without interest, equal to the cumulative dividends declared or paid on a Share,
if any, during such period multiplied by the number of unvested RSUs. The dividend equivalents in respect of vested RSUs shall
be paid in cash or Shares, as applicable, on the Vesting Date. If the Participant’s membership on the Board terminates prior
to an applicable Vesting Date for any reason set forth in Section (C)(1) of this Director Award Agreement or if a Change of Control
occurs, the Participant shall be entitled to receive all accrued and unpaid dividend equivalents at the time the RSUs are settled
in accordance with Sections (C)(1) or (D), as applicable. If the Participant’s membership on the Board terminates prior to
an applicable Vesting Date for any reason set forth in Section (C)(2), any accrued and unpaid dividend equivalents shall be forfeited.

		(C)	Termination of Membership on the Board.

		(1)	If, after the Date of Award and prior to an
applicable Settlement Date, the Participant’s membership on the Board terminates by reason of the Participant’s death,
Disability (defined below) or an Approved Departure (defined below), the RSUs, to the extent unvested, shall vest immediately and
shall settle through the delivery of Shares and cash pursuant to Section (B)(2) within forty-five (45) days following the termination.
For the purposes of this Director Award Agreement, “Disability” shall be defined as a physical or mental impairment
sufficient to make a Participant unable to perform the services required of a member of the Board, as determined by the Committee.
“Approved Departure” shall be defined as a termination of the Participant’s membership on the Board, including
a resignation from the Board by the Participant or a Participant not standing for re-election to the Board, provided that such
termination is approved in advance by the Board. Notwithstanding the foregoing, a termination resulting from (i) the Participant’s
willful and continued failure to substantially perform his or her duties as a member of the Board, (ii) an

     

     

    

act of fraud or an intentional misrepresentation
by the Participant or (iii) the Participant’s commission of a felony, in each such case, as determined by the Board in its
sole discretion, shall not constitute an Approved Departure.

		(2)	If, prior to an applicable Vesting Date, the
Participant’s membership on the Board terminates for any reason other than as set forth in Section (C)(1), the unvested RSUs
shall be cancelled immediately and the Participant shall immediately forfeit any rights to, and shall not be entitled to receive
any Shares or cash payments with respect to, the RSUs including, without limitation, dividend equivalents pursuant to Section (B)(4).

		(D)	Change of Control. Notwithstanding any provision contained in the Plan or this Director
Award Agreement to the contrary, if, prior to an applicable Vesting Date, a Change of Control occurs, the RSUs, to the extent unvested,
shall vest and settle immediately upon the effective date of the Change of Control.

		(E)	Transferability. RSUs are not transferable other than by last will and testament,
by the laws of descent and distribution pursuant to a domestic relations order, or as otherwise permitted under Section 12 of the
Plan.

		(F)	Incorporation of Plan. The Plan provides a
complete description of the terms and conditions governing all Awards granted thereunder and is incorporated into this Director
Award Agreement by reference. This Director Award Agreement and the rights of the Participant hereunder are subject to the terms
and conditions of the Plan, as amended from time to time, and to such rules and regulations as the Committee may adopt under the
Plan. If there is any inconsistency between the terms of this Director Award Agreement and the terms of the Plan, the Plan’s
terms shall supersede and replace the conflicting terms of this Director Award Agreement.

		(G)	No Rights as a Stockholder. A Participant will have no rights as a stockholder with
respect to Shares covered by this Director Award Agreement (including voting rights) until the date the Participant or his nominee
becomes the holder of record of such shares on an applicable Settlement Date.

		(H)	Miscellaneous

		(1)	It is expressly understood that the Committee
is authorized to administer, construe, and make all determinations necessary or appropriate to the administration of the Plan and
this Director Award Agreement, all of which shall be binding upon the Participant.

		(2)	The Board may at any time, or from time to
time, terminate, amend, modify or suspend the Plan, and the Board or the Committee may amend or modify this Director Award Agreement
at any time; provided, however, that, except as provided herein, no termination, amendment, modification or suspension
shall materially and adversely alter or impair the rights of the Participant under this Director Award Agreement, without the Participant’s
written consent. 

		(3)	If any provision of the Plan or the Director
Award Agreement would, in the reasonable good faith judgment of the Committee, result or likely result in the imposition on the
Participant, a beneficiary or any other person of a penalty tax under Section 409A of the Code and the regulations and guidance
promulgated thereunder (“Section 409A”), the Committee may modify the terms of the Plan or the Director Award
Agreement, without the consent of the Participant, beneficiary or such other person, in the manner that the Committee may reasonably
and in good faith determine to be necessary or advisable to avoid the imposition of such penalty tax. Notwithstanding anything
to the contrary in the Plan or the Director Award Agreement, to the extent that the Participant is a “Specified Employee”
(within the meaning of the Committee’s established methodology for determining “Specified Employees” for
purposes of Section 409A), payment or distribution of any amounts with respect to the RSUs that are subject to Section 409A will
be made as soon as practicable following the first business day of the seventh month following the Participant’s Separation
from Service from the Company Group or, if earlier, the date of the Participant’s death.

		(4)	Delivery of the Shares underlying the RSUs
or payment in cash, as applicable, upon settlement is subject to the Participant satisfying all applicable federal, state, local
and foreign taxes. The Company shall have the power and the right to (i) deduct or withhold from all amounts payable to the Participant
pursuant to the RSUs or otherwise, or (ii) require the Participant to remit to the Company, an amount sufficient to satisfy any
applicable taxes required by law. Further, the Company may permit or require the Participant to satisfy, in whole or in part, the
tax obligations by withholding Shares that would otherwise be received upon settlement of the RSUs. 

		(5)	This Director Award Agreement shall be subject
to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges
as may be required, or the Committee determines are advisable. The Participant agrees to take all steps the Company determines
are necessary to comply with all applicable provisions of federal and state securities law in exercising his or her rights under
this Director Award Agreement.

		(6)	Nothing in the Plan or this Director Award
Agreement should be construed as providing the Participant with financial, tax, legal or other advice with respect to the RSUs.
The Company recommends that the Participant consult with his or her financial, tax, legal and other advisors to provide advice
in connection with the RSUs. 

    2

     

    

		(7)	All obligations of the Company under the Plan
and this Director Award Agreement, with respect to the Awards, shall be binding on any successor to the Company, whether the existence
of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially
all of the business and/or assets of the Company.

		(8)	To the extent not preempted by federal law,
this Director Award Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware.

		(I)	Acceptance of Award. Acceptance of this Award requires no action on the part of the
Participant and the Participant will be deemed to have agreed to all terms and conditions hereof. If the Participant desires to
refuse the Award, the Participant must notify the Company in writing. Such notification should be sent to CIT Group Inc., Human
Resources Department, 1 CIT Drive, Livingston, New Jersey 07039, no later than thirty (30) days after receipt of this Director
Award Agreement.

 

IN WITNESS WHEREOF, this Director
Award Agreement has been executed by the Company by one of its duly authorized officers as of the Date of Award.

CIT Group Inc.

 

 

 

 

    3FIRST AMENDMENT TO EXCLUSIVE CHANNEL COLLABORATION AGREEMENT

 Exhibit 10.10 

FIRST AMENDMENT TO EXCLUSIVE CHANNEL COLLABORATION AGREEMENT 

THIS FIRST AMENDMENT (the “Amendment”) is entered into as of this 21st
day of July, 2016 and serves to amend the Exclusive Channel Collaboration Agreement entered into by and between Intrexon Corporation (“Intrexon”) and Oragenics, Inc. (“Oragenics”) on June 5, 2012 (the “Agreement”).
All capitalized terms not defined herein shall have the meaning set forth in the Agreement. 
 WHEREAS, Intrexon has expertise
in and owns or controls proprietary technology relating to the identification, design and production of genetically modified cells and DNA vectors, and the control of expression of proteins and bioactive RNA species; and 

WHEREAS, pursuant to the Agreement, Oragenics is currently Intrexon’s exclusive channel collaborator with the right to use
Intrexon technology to research, develop and commercialize products for use in a specific Field (as defined in the Agreement); and 

WHEREAS, Oragenics and Intrexon now mutually desire to broaden the scope of its rights under the Agreement in order to research,
develop and commercialize products for use in an expanded Field as more fully described below. 
 NOW THEREFORE, in
consideration of the foregoing and the covenants and promises contained herein, the Parties hereby agree to amend the Agreement pursuant to Section 12.7 thereof as follows: 

1. Section 1.20 of the Agreement is hereby replaced in its entirety with the following: 

1.20 “Field” means, irrespective of whether such requires regulatory approval (a) the direct administration to humans or other
animals of a Lantibiotic as an active pharmaceutical ingredient in drug products for the prevention or treatment of infectious disease, and/or (b) the direct administration to humans or other animals of Streptococcus mutans that is
genetically modified to express a Lantibiotic in vivo as an active pharmaceutical ingredient in drug products for the prevention or treatment of infectious disease.” 

2. Oragenics hereby represents and warrants to Intrexon that, as of the date of this Amendment: 

 

	 	a.	Corporate Power. Oragenics is duly organized and validly existing under the laws of Florida and has full corporate power and authority to enter into this Amendment and to carry out the provisions hereof.

  

	 	b.	Due Authorization. Oragenics is duly authorized to execute and deliver this Amendment and to perform its obligations hereunder, and the person executing this Amendment on Oragenics’ behalf has been duly
authorized to do so by all requisite corporate action. 

 3. Intrexon hereby represents and warrants to Oragenics that, as of
the date of this Amendment: 

	 	a.	Corporate Power. Intrexon is duly organized and validly existing under the laws of Virginia and has full corporate power and authority to enter into this Amendment and to carry out the provisions hereof.

  

	 	b.	Due Authorization. Intrexon is duly authorized to execute and deliver this Amendment and to perform its obligations hereunder, and the person executing this Amendment on Intrexon’s behalf has been duly
authorized to do so by all requisite corporate action. 

 4. All other terms and conditions of the Agreement remain in full
force and effect. 
 [Signature Page Follows] 

 IN WITNESS WHEREOF, the parties hereto have duly executed this First Amendment to
Exclusive Channel Collaboration Agreement by authorized representatives as of the date written above. 
 INTREXON CORPORATION 

By: /s/Jeffrey Perez 
 Name: Jeffrey Perez 

Title: SVP, Intellectual Property Affairs 
 ORAGENICS, INC.

 By: /s/ Alan F. Joslyn 
 Name: Alan F. Joslyn

 Title: Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}]]